Company news

Tiziana Life Sciences Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021

September 23, 2021

Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings

September 2, 2021

Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation and, if approved, the delisting of its ordinary shares in London and the direct listing of common shares in the new parent company of the Tiziana group on NASDAQ

August 19, 2021

Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil

August 16, 2021

Tiziana Life Sciences plc (the "Company") Result of Annual General Meeting

June 24, 2021

Tiziana Enters a Collaboration Agreement with FHI Clinical to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

June 22, 2021

Tiziana Appoints Dr. Kevin Schutz as Vice-President of Regulatory Affairs

June 20, 2021

Tiziana Life Sciences plc ("Tiziana" or the “Company”) Posting of Notice of Annual General Meeting

June 1, 2021

Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers

May 25, 2021

Tiziana Life Sciences Announces Initiation of Clinical Trial in a Secondary Progressive Multiple Sclerosis (SPMS) Patient with Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access P...

May 24, 2021

Tiziana Announces Strategic Initiative with Takanawa Japan K.K., Pharma Team, to Identify a Partner in Japan and Other Asian Countries for Further Clinical Development of Milciclib in Patients with Advanced Hepatocellular Carcinoma.

May 4, 2021

Tiziana Life Sciences plc Announces Plans to List Accustem Sciences Limited in the U.S.

April 12, 2021

Tiziana Announces the FDA Has Allowed Treatment for a Secondary Progressive Multiple Sclerosis (SPMS) Patient for the Nasal Administration of Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, Under an Individual Patient Expanded Access Program

March 29, 2021

Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director

February 4, 2021

Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil

February 1, 2021

Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission

January 26, 2021

Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market

January 19, 2021

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

January 12, 2021

Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil

January 3, 2021

Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Publication of Prospectus

December 17, 2020

Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM

December 16, 2020

Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4: 15 p.m. ET

November 30, 2020

Tiziana Life Sciences PLC ("Tiziana" or the "Company") - PDMR Dealing

November 17, 2020

Tiziana Life Sciences announces collaboration with Parexel Biotech to conduct phase 1b/2 clinical trial in patients with Crohn’s Disease

November 10, 2020

Tiziana Announces Initiation of Clinical Trial with Covid-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody

November 1, 2020

Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)

October 26, 2020

Tiziana Life Sciences Plc (the "Company") - Result of General Meeting

October 1, 2020

Tiziana Life Sciences plc to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil

September 16, 2020

Tiziana Life Sciences Announces Planned Spin Out of StemPrintER into a New Publicly Listed Company, Accustem Sciences

September 15, 2020

Tiziana Life Sciences Clarifies Reason for Filing an Amended ADS Registration Statement

August 27, 2020

Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for COVID-19 and other pulmonary diseases

August 23, 2020

Tiziana Granted a Patent on the Use of Milciclib in Combination with Tyrosine Kinase Inhibitors for Treatment of Hepatocellular Carcinoma and other Cancers

August 20, 2020

Tiziana is Pleased to Retain Dr. Napoleone Ferrara to Serve on Its Scientific Advisory Board for an Additional Three-Year Term

August 19, 2020

Tiziana Granted a Patent on Methods and Use of Anti-CD3 Monoclonal Antibodies for Treatment of Crohn’s Disease

August 17, 2020

Tiziana Life Sciences plc Announces Closing of $57.25 Million Offering

August 4, 2020

Tiziana Life Sciences Announces an Expedited Clinical Development Plan for Its Anti-Interleukin-6-Receptor, a Fully Human Monoclonal Antibody, for the Treatment of COVID-19 Patients

August 3, 2020

Tiziana Announces Pricing of U.S. Follow-On Offering of ADSs Raising $57.25 million

August 2, 2020

Tiziana Life Sciences plc: Total Voting Rights

July 30, 2020

Tiziana Life Sciences plc: Early notification of proposed admission to the Official List and cancellation of trading on AIM

July 29, 2020

Exercise of Warrants and Issue of Equity and Total Voting Rights

July 23, 2020

Tiziana Life Sciences plc ("Tiziana" or the "Company") Director Appointment

July 19, 2020

Tiziana Announces Submission of Patent Application on Use of Foralumab, the Only Fully Human Anti-CD3 Monoclonal Antibody, to Enhance Success of CAR-T Therapy

July 15, 2020

Tiziana Life Sciences plc Change to ADS Ratio

July 14, 2020

Tiziana Life Sciences PLC Directorate Change

June 17, 2020

← Newer news releases

Decks

The 5 newest of 13 decks. Every deck is listed under its year.